School of Basic Medical Sciences, Chengdu University, Chengdu, China.
State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao, China.
J Ethnopharmacol. 2022 May 10;289:115002. doi: 10.1016/j.jep.2022.115002. Epub 2022 Jan 20.
Buxue Yimu Pills (BYP) is a well-known traditional Chinese medicine prescription which is clinical used in gynecology and obstetrics, and is documented to exhibit therapeutic potential to defective angiogenesis and impaired blood flow.
This study aimed to investigate the effects and biological mechanisms of BYP in improvement of defective angiogenesis and impaired blood flow which represent major health issues associated with various diseases including postpartum or abortion complications.
In this study, VEGFR tyrosine kinase inhibitor II (VRI) was used to establish blood vessel loss model in Tg(fli-1a:EGFP) zebrafish embryos. Blood vessel loss was calculated, and quantitative real-time PCR (qRT-PCR) assay was performed to detect gene expression. Mifepristone and misoprostol were applied to construct a medical-induced incomplete abortion rats model. Whole blood viscosity indexes, hemorheology and coagulation function of the rats were investigated. Immunohistochemistry analysis was used for evaluation of the uterine tissues.
BYP treatment significantly promoted angiogenesis as evidenced by the restoration of VRI-induced blood vessel loss in zebrafish embryos. BYP treatment effectively reversed VRI-induced down-regulation of the VEGFRs (Kdr, Kdrl and Flt1). Furthermore, BYP administration significantly suppressed the increase of whole blood viscosity indexes, and remarkably shortened the levels of prothrombin time and activated partial thromboplastin time in the medical-induced incomplete abortion rats, indicating the improvement of hemorheology and coagulation function. Immunohistochemistry analysis suggested that BYP administration increased the expression level of VEGFR2 in uterus tissues of the rats.
BYP exhibits therapeutic effects in promoting angiogenesis and blood circulation, and mitigating blood stasis, supporting its clinical application for postpartum or abortion complications.
补血益母丸(BYP)是一种著名的中药方剂,临床上用于妇科和产科,具有治疗血管生成缺陷和血流受损的潜力。
本研究旨在探讨 BYP 改善血管生成缺陷和血流受损的作用及其生物学机制,这些缺陷和受损与各种疾病相关,包括产后或流产并发症。
在这项研究中,使用 VEGFR 酪氨酸激酶抑制剂 II(VRI)建立 Tg(fli-1a:EGFP)斑马鱼胚胎血管损失模型。计算血管损失,并进行定量实时 PCR(qRT-PCR)检测基因表达。米非司酮和米索前列醇用于构建医学诱导的不完全流产大鼠模型。研究大鼠的全血黏度指标、血液流变学和凝血功能。采用免疫组织化学分析评估子宫组织。
BYP 治疗显著促进了血管生成,这可以通过斑马鱼胚胎中 VRI 诱导的血管损失的恢复来证明。BYP 治疗有效逆转了 VRI 诱导的 VEGFRs(Kdr、Kdrl 和 Flt1)下调。此外,BYP 给药显著抑制了医学诱导的不完全流产大鼠全血黏度指标的升高,并显著缩短了凝血酶原时间和活化部分凝血活酶时间,表明血液流变学和凝血功能得到改善。免疫组织化学分析表明,BYP 给药增加了大鼠子宫组织中 VEGFR2 的表达水平。
BYP 具有促进血管生成和血液循环、缓解血瘀的治疗作用,支持其在产后或流产并发症的临床应用。